Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00960856 · ClinicalTrials.gov registry record · Phase 1
Four Arm Food Effect Study of Fenofibric Acid Tablets
A Phase 1 study, sponsored by Mutual Pharmaceutical Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00960856 is a Phase 1 study that has completed, run by Mutual Pharmaceutical Company. The registered enrollment target is 40 participants.
The verdict
NCT00960856, a Phase 1 study, has completed, sponsored by Mutual Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this study is to characterize the single-dose pharmacokinetic profile of fenofibric acid (105 mg tablets) and the effect of food of various calorie/fat compositions on the rate and extent of absorption. Additionally, the safety and tolerability of this dose and regimen of fenofibric acid will be evaluated.
Interventions
- DRUG Fenofibric Acid 105 mg Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00960856
The ClinicalTrials.gov registry entry for NCT00960856 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mutual Pharmaceutical Company, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fenofibric Acid 105 mg Tablet is the first listed.
NCT00960856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00960856 about?
NCT00960856 is a clinical study titled "Four Arm Food Effect Study of Fenofibric Acid Tablets". The primary objective of this study is to characterize the single-dose pharmacokinetic profile of fenofibric acid (105 mg tablets) and the effect of food of various calorie/fat compositions on the rate and extent of absorption. Additionally, the safety and tolerability of this dose and regimen of fe...
What is the current status of trial NCT00960856?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2007-11. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00960856?
The interventions under investigation include: Fenofibric Acid 105 mg Tablet (DRUG).
Who is sponsoring clinical trial NCT00960856?
This trial is sponsored by Mutual Pharmaceutical Company, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.